Patient FAQs

Treatments take place at your MacuMira provider’s eye care office, with each session lasting about 32 minutes.

During the treatment, you will be seated or reclined while a headset is placed over your eyes.

Contoured eye cups rest gently on your closed eyelids, delivering microcurrent stimulation to the retina. Many patients find it relaxing enough to fall asleep during treatment.

Some patients experience a mild tingling sensation or brief patterns of light during the session. These are known as phosphenes and are a normal response to the stimulation.

After the session, you can continue with your day as normal with no downtime or restrictions.

Find a MacuMira provider near you with our map tool. If there’s not currently someone in your area, please contact us to be informed of new providers near you.

No, MacuMira treatment isn’t painful, and there are no needles or drugs involved. It’s completely noninvasive.

Some patients feel a slight tingling sensation during the session, but it’s generally very comfortable and well-tolerated.

Most patients report vision improvements within the first 10 days of treatment.

Results vary, but many dry AMD patients describe better contrast (ability to see detail in dim light), sharper reading vision, or less glare sensitivity after the initial 10-day phase of treatment.

Unfortunately, there is currently no cure for dry AMD. MacuMira is not a cure. However, it may help improve functional vision and slow progressive vision loss in people with dry AMD.

Many patients who receive MacuMira begin to notice improvements within the first 10 days during the initial loading phase of treatment.

To maintain those gains, follow-up treatments are typically recommended at least every 3 months. Your eye care provider will determine the ideal schedule based on your condition and how your vision responds.

Yes, MacuMira can be used alongside your current vision aids and AREDS or AREDS2 supplements. It doesn’t interfere with any other aspects of your eye care.

Yes! MacuMira is a noninvasive treatment that has demonstrated a clinically proven strong safety profile. It has undergone rigorous safety review and licensing by Health Canada and meets the standards required of Class II medical devices.

The stimulation uses microcurrent levels that are incapable of causing muscle contraction and remain well below thresholds associated with discomfort or tissue damage.

No adverse events were reported in the prospective clinical study, and the treatment has now been used in clinical settings with excellent tolerability across thousands of treatment sessions.

Patients typically find the treatment comfortable and easy to complete. It doesn’t involve pills, lasers, injections, or any surgery.

MacuMira is a safe and noninvasive treatment, but it is not suitable for everyone. People with certain medical devices or conditions should avoid treatment, including:

• Individuals with a pacemaker or other implantable cardiac device
• People with cochlear implants or other electronic implants near the eyes
• Anyone with active eye infections or recent ocular surgery
• Women who are pregnant or breastfeeding (consult your eye care provider first)

Your eye care provider will review your medical history before treatment to ensure MacuMira is safe for you.

There are currently no other authorized treatments for dry AMD, and nothing else has been shown to improve vision lost to dry AMD.

After diagnosing early stage dry AMD, eye care providers typically recommend lifestyle changes such as healthy eating, quitting smoking, and regular exercise to potentially slow the progression of dry AMD.

For intermediate dry AMD, eye care providers typically recommend dietary supplements, such as AREDS or AREDS2 vitamins. These may slow the progression of the disease, but do not improve vision.